Confirmatory Analysis of QUARTZ Study Results: Survival Prolongation After Whole-brain Radiotherapy

Background/Aim: The aim of this study was to analyze the survival of patients with brain metastases treated with best supportive care or additional whole-brain radiotherapy (WBRT), in order to confirm results from the prospective randomized QUARTZ study, which suggested prolonged survival after WBRT (5 fractions of 4 Gy) if favorable prognostic factors were present (age younger than 60 years, graded prognostic assessment score 2.5-3 points). Patients and Methods: We performed a retrospective single institution analysis of 76 patients with favorable prognosis. In contrast to the QUARTZ trial, inclusion was not limited to patients with non-small cell lung cancer (NSCLC). Furthermore, a cohort treated with higher total doses of WBRT was included (10 fractions of 3 Gy). Results: All patients were younger than 60 years or had a graded prognostic assessment score of 2.5-3. The median survival was significantly shorter after best supportive care (1.2 months; 3.2 months after WBRT with 5 fractions of 4 Gy and 3.9 months after 10 fractions of 3 Gy). Also, in multivariate analyses, survival was significantly better after WBRT. Further favorable prognostic factors included better performance status, no or limited extracranial metastases and primary tumor other than gastrointestinal. Conclusion: In line with the QUARTZ trial results, WBRT prolonged survival in patients with favorable prognostic features.

[1]  C. Nieder,et al.  External Validation of the LabBM Score in Patients With Brain Metastases , 2019, Journal of clinical medicine research.

[2]  R. Soffietti,et al.  Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC). , 2019, Lung cancer.

[3]  M. Flentje,et al.  External validation of a prognostic score predicting overall survival for patients with brain metastases based on extracranial factors , 2019, Clinical and translational radiation oncology.

[4]  Timothy K. Nguyen,et al.  Management of patients with brain metastases from non-small cell lung cancer and adverse prognostic features: multi-national radiation treatment recommendations are heterogeneous , 2019, Radiation Oncology.

[5]  Y. Tomita,et al.  Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases , 2019, AntiCancer Research.

[6]  D. Rades,et al.  Whole-Brain Radiotherapy (WBRT) for Brain Metastases: Does the Interval Between Imaging and Treatment Matter? , 2018, AntiCancer Research.

[7]  P. Brown,et al.  Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool , 2018, Neuro-oncology.

[8]  D. Rades,et al.  A Specific Survival Score for Patients Receiving Local Therapy for Single Brain Metastasis from a Gynecological Malignancy , 2018, In Vivo.

[9]  A. Grosu,et al.  Local control and possibility of tailored salvage after hypofractionated stereotactic radiotherapy of the cavity after brain metastases resection , 2018, Cancer medicine.

[10]  D. Rades,et al.  Validation of a Survival Score for Patients Receiving Radiosurgery or Fractionated Stereotactic Radiotherapy for 1 to 3 Brain Metastases. , 2018, In vivo.

[11]  P. Koper,et al.  Survival after whole brain radiotherapy for brain metastases from lung cancer and breast cancer is poor in 6325 Dutch patients treated between 2000 and 2014 , 2017, Acta oncologica.

[12]  P. Brown,et al.  Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution? , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Wen Jiang,et al.  Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). , 2017, International journal of radiation oncology, biology, physics.

[14]  Takao Takahashi,et al.  Predicting prognosis of short survival time after palliative whole-brain radiotherapy , 2017, Journal of radiation research.

[15]  A. Nanda,et al.  Long-term Survival After Stereotactic Radiosurgery of Brain Metastases: A Case Series with 10-year Follow-up. , 2017, Anticancer research.

[16]  A. Grosu,et al.  Short Survival Time after Palliative whole Brain Radiotherapy: Can We Predict Potential Overtreatment by Use of a Nomogram? , 2017, Journal of Cancer.

[17]  Esther G C Troost,et al.  Individualized early death and long-term survival prediction after stereotactic radiosurgery for brain metastases of non-small cell lung cancer: Two externally validated nomograms. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  Alexander Radbruch,et al.  Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO) , 2017, Neuro-oncology.

[19]  Ruth E Langley,et al.  Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial , 2016, The Lancet.

[20]  L. Frings,et al.  Whole brain irradiation with hippocampal sparing and dose escalation on multiple brain metastases , 2015, Strahlentherapie und Onkologie.

[21]  C. Nieder,et al.  Prognostic models predicting survival of patients with brain metastases: integration of lactate dehydrogenase, albumin and extracranial organ involvement. , 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

[22]  Xianghua Luo,et al.  Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Nieder,et al.  Serum Lactate Dehydrogenase Contributes to Prognostic Assessment in Patients With Oligometastatic Cancer and Brain Involvement , 2018, In Vivo.

[24]  L. Collette,et al.  A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.